The Life Sciences “multi stage” and “bridge” fund

The objective of Alta Life Sciences Spain I (“Alta”) is to promote the financing of the life science industry in Spain

Alta Life Sciences was born of the desire to unite Altamar Capital Partners with an extraordinary team with great life sciences company investment experience, led by Guy Nohra and aided by Montserrat Vendrell, Miguel Valls and Scott Moonly. The objective is to turn this into one of the most important life science investment vehicles in Spain. The new team is based in Barcelona.

Its first fund, Alta Life Sciences Spain I, invests in companies across a range of growth and development phases. It covers all areas, including biotechnology, medical devices, diagnostics, genomes and digital health.

Alta Life Sciences aims to serve as a bridge between the two sides of the Atlantic, linking Spain’s scientific ecosystem with Silicon Valley’s knowhow. Alta invests in companies based in Spain or foreign firms seeking a foothold the country. There are several reasons that make Spain an ideal place to invest in this sector.

Altamar integrates environmental, social and corporate governance (“ESG”) factors by implementing best market practices at all stages of the investment process. Thus, ESG factors are taken into account in the selection and analysis of investments (as part of the Due Diligence process), in the formalization of investments (by requesting ESG clauses from managers in the Side Letters and the Exclusion Policy) and in the monitoring of investments (by updating the ESG Due Diligence Checklist, analyzing the reporting on sustainability issued by managers and the ESG information collected by Altamar’s investment teams when attending their Annual Meetings).

The Alta team summarizes them in four points:

Funds under management